News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
GlaxoSmithKline Says Advair Shows Edge over Spiriva in COPD
December 28, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Reuters) - GlaxoSmithKline Plc said on Friday that clinical trial results showed its top-seller Advair had an edge over Pfizer Inc's (PFE.N: Quote, Profile, Research) rival product Spiriva in treating patients with the lung disease COPD.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
Pfizer
GSK
MORE ON THIS TOPIC
Neuropsychiatric disorders
Vistagen in freefall as social anxiety drug fails Phase 3
July 1, 2026
·
2 min read
·
Tristan Manalac
Podcast
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
July 1, 2026
·
2 min read
·
Jef Akst
Insights
Golden Triangle still dominates, but talent and capital gaps slow biotech growth
July 1, 2026
·
3 min read
·
Jennifer C. Smith-Parker
Job Trends
Opinion: Innovation wins the contract. Complexity loses the renewal
July 1, 2026
·
3 min read
·
Antonio Serrano
